| ID | Sequence | Length | GC content |
|---|---|---|---|
| AGUGCCUGUAUGUGUGUGAGUGUGAGAGAAUGUGUGCGUGCGUGUGUGU… | 3149 nt | 0.5557 | |
| CUCUUAUCUUCAUCAUCGCUCUACAUCCACGAACAUUUCCUGAGCUCCU… | 2241 nt | 0.5493 | |
| AUUCACUGAUUAGAUCCAGCGCUGAGAGGCAGCACUGCUCCUUCUCUCA… | 3120 nt | 0.5577 | |
| AUUCACUGAUUAGAUCCAGCGCUGAGAGGCAGCACUGCUCCUUCUCUCA… | 3116 nt | 0.5578 | |
| GGAGAGCUUCCGUGUGGCCCCCCGGGCGAGGCCGCCCACGGUGGUGAGG… | 3056 nt | 0.5658 | |
| AGGGCCAACAUGGCCGCCGCCGCCGCUUGGAGCUGAAGUGCCGCCGCCG… | 2062 nt | 0.5820 | |
| AUUCACUGAUUAGAUCCAGCGCUGAGAGGCAGCACUGCUCCUUCUCUCA… | 3042 nt | 0.5572 |
Enables beta-catenin binding activity. Involved in positive regulation of canonical Wnt signaling pathway. Acts upstream of or within positive regulation of DNA-binding transcription factor activity and protein monoubiquitination. Located in nuclear lamina and nucleoplasm. Part of protein-containing complex. Implicated in hypomyelinating leukodystrophy 23. [provided by Alliance of Genome Resources, Jul 2025]
A study in mice demonstrated that the RNF220 is a previously reported circular RNA (circRNA) [Memczak et al. DOI:10.1038/nature11928]. A study in human patients with heart failure after acute myocardial infarction demonstrated that the RNF220 was significantly upregulated in peripheral blood mononuclear cells from individuals exhibiting sacubitril/valsartan resistance compared to non-resistant patients, as validated by quantitative real-time PCR in 18 sample pairs [Su et al. DOI:10.1016/j.ejphar.2023.175547].